Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Janssen-Cilag’s Darzalex -SC based quadruplet regimen gets European approval to treat patients with newly diagnosed MM who are transplant-eligible: Beerse, Belgium Thursday, Oct ...

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $266.48 and traded as low as ...

J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...

Johnson & Johnson (J&J) raised its 2024 profit and sales forecasts on October 15, thanks to strong sales of oncology drugs, ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

On Oct. 15, J&J JNJ announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative ...

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...